Ying Zhu, Lian Chen, Jing Su, Yao Liu, Yuxi Ma, Xiaofang Dai, Tao Zhang, Wenshan He, Jinghua Ren
{"title":"Postoperative bacterial infection promotes tumor metastasis via neutrophil-mediated NK cell dysfunction.","authors":"Ying Zhu, Lian Chen, Jing Su, Yao Liu, Yuxi Ma, Xiaofang Dai, Tao Zhang, Wenshan He, Jinghua Ren","doi":"10.1186/s12935-026-04441-w","DOIUrl":"https://doi.org/10.1186/s12935-026-04441-w","url":null,"abstract":"<p><strong>Background: </strong>Distant metastasis is the leading cause of cancer-related mortality, and inflammation plays a significant role in promoting cancer metastasis. Patients undergoing surgery are generally more susceptible to bacterial infection due to surgical trauma and immunological dysfunction. However, the extent to which bacterial inflammation contributes to tumor progression remains unclear.</p><p><strong>Methods: </strong>We conducted an integrative analysis of colorectal cancer patients who underwent curative surgery and experimental animal models to investigate the impact of anastomotic leakage on oncological outcomes. Using a cecal ligation and puncture (CLP) mouse model, we analyzed NK cell infiltration and activity in peripheral blood and liver tissues under infectious inflammatory conditions, together with NET deposition in metastatic niches. Finally, we examined the efficacy of NET degradation or CTSG inhibition in restoring NK cell-mediated tumor cytotoxicity and preventing tumor metastasis in two distinct mouse models of severe infection.</p><p><strong>Results: </strong>Postoperative infectious complications were associated with increased metastatic recurrence. In mouse models, infection-induced NETs impaired NK cell proliferation and function. Mechanistically, NET-associated CTSG contributed to reduced surface NKp46 expression, a key activating receptor on NK cells. Disruption of NETs or pharmacological inhibition of CTSG restored NK cell cytotoxicity and suppressed metastatic colonization.</p><p><strong>Conclusion: </strong>NET-associated CTSG undermines NK cell-mediated tumor surveillance, contributing to infection-driven metastasis. Targeting the NET-CTSG axis may offer a novel therapeutic strategy to prevent postoperative metastatic progression.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Illa Tea, Marine P M Letertre, Julien Boccard, Anne-Marie Schiphorst, Sophie Blanchet, Mikael Croyal, Anneke C Blackburn, Guillaume Tcherkez
{"title":"Breast cancer metabolism and responsiveness to dichloroacetate: relationships with <sup>15</sup>N and <sup>13</sup>C natural abundance.","authors":"Illa Tea, Marine P M Letertre, Julien Boccard, Anne-Marie Schiphorst, Sophie Blanchet, Mikael Croyal, Anneke C Blackburn, Guillaume Tcherkez","doi":"10.1186/s12935-026-04446-5","DOIUrl":"10.1186/s12935-026-04446-5","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming is a hallmark of breast cancer (BrCa), with alterations in glycolysis, glutamine metabolism, and the urea cycle contributing to tumour progression. Dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, shifts metabolism toward oxidative phosphorylation and has been proposed as a therapeutic agent. While isotope tracing is well-established, natural isotope abundance (δ¹³C, δ¹⁵N) is emerging as a biomarker of metabolic alterations in cancer.</p><p><strong>Methods: </strong>We investigated the relationship between isotope composition and metabolism in BrCa using two BALB/c mouse mammary tumour models (V14 and 4T1) and assessed the effects of DCA treatment using metabolomics, lipidomics and isotopomics.</p><p><strong>Results: </strong>V14 and 4T1 tumours exhibited isotopic patterns similar to human tumours, with δ¹³C enrichment and δ¹⁵N depletion relative to non-cancerous mammary tissue. V14 tumours were more δ¹⁵N-depleted than 4T1, reflecting differences in nitrogen metabolism. Multivariate analysis integrating isotopic, metabolomic, and lipidomic data revealed isotopic features as key discriminators between tumours and normal tissues. Compared to V14, 4T1 tumours were enriched in TCA intermediates, sphingolipids, and amino acids, whereas V14 tumours showed elevated glutaminolytic and nitrogenous metabolites. DCA treatment differentially affected tumour growth, with V14 tumours more sensitive than 4T1. DCA altered nitrogen metabolism, increasing the arginine-to-ornithine ratio, and modulating δ¹⁵N values in a tumour-specific manner increasing V14 and decreasing 4T1 δ¹⁵N values. DCA had little effect on δ¹³C. δ¹³C values were primarily determined by the balance between lipid and TCA cycle metabolites, rather than glycolytic flux. δ¹⁵N variation was linked to nitrogen metabolism, including urea cycle intermediates and sphingolipid composition, with a potential role for choline-related fractionation in δ¹⁵N depletion. Altered gene expression of Hacd2 and Acot12 in V14 tumours after DCA treatment was reflected in shorter fatty acid tails in phosphatidyl cholines, supporting the lipidomics data.</p><p><strong>Conclusions: </strong>These findings support the hypothesis that cancer-associated metabolic reprogramming influences natural isotope abundance. Correlations between isotope shifts and metabolic signatures highlight the potential of lipid-derived δ¹⁵N as a biomarker of tumour metabolic state, with implications for noninvasive metabolic profiling in BrCa.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13757042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tina Haghi, Asma Yazdani, Seyed Ahmad Ebrahimi, Maryam Memarzadeh, Hosna Yazdani, Ali Asadirad, Leili Aghebati-Maleki
{"title":"Nanoparticle-based photodynamic therapy and immune checkpoint modulation: a new frontier in cancer immunotherapy.","authors":"Tina Haghi, Asma Yazdani, Seyed Ahmad Ebrahimi, Maryam Memarzadeh, Hosna Yazdani, Ali Asadirad, Leili Aghebati-Maleki","doi":"10.1186/s12935-026-04436-7","DOIUrl":"10.1186/s12935-026-04436-7","url":null,"abstract":"<p><p>Nanoparticle-mediated photodynamic therapy (PDT) is gaining increasing attention as a complementary strategy to enhance the efficacy of immune checkpoint blockade (ICB) in solid tumors. PDT induces reactive oxygen species-mediated cytotoxicity and immunogenic cell death, promoting antigen release, dendritic cell maturation, and remodeling of the tumor microenvironment to support systemic antitumor immunity. However, clinical outcomes remain constrained by hypoxia, suboptimal photosensitizer delivery, and limited intratumoral nanoparticle penetration. Recent advances in multifunctional biodegradable nanocarriers engineered to co-deliver photosensitizers together with oxygen-generating or oxygen-carrying components, and immunomodulatory agents have shown potential to overcome these barriers and enhance antitumor immune responses in preclinical settings. In this review, we critically evaluate the current landscape of nanotechnology-enhanced PDT combined with ICB, outline emerging design principles that may improve therapeutic specificity and immune activation, and highlight translational implications for clinical application. We further discuss the role of artificial intelligence (AI) in guiding PDT parameters, predicting immune checkpoint responsiveness, and informing rational nanoplatform design. Finally, persisting challenges, including standardized characterization, regulatory harmonization, scalable manufacturing, and long-term biosafety, are considered, emphasizing the need for coordinated multidisciplinary efforts to advance nanotechnology-assisted PDT-immunotherapy combinations toward clinically viable cancer treatments.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kiavash Hushmandi, Hassan Abolghasemi, Russel J Reiter, Abbas Ali Imani Fooladi, Najma Farahani, Liping Liang, William C Cho, Shokooh Salimimoghadam, Mina Alimohammadi, Le Liu, Gautam Sethi
{"title":"Interplay of non-coding RNAs with amino acid and glucose transporters within the solute carrier family in cancer: a review.","authors":"Kiavash Hushmandi, Hassan Abolghasemi, Russel J Reiter, Abbas Ali Imani Fooladi, Najma Farahani, Liping Liang, William C Cho, Shokooh Salimimoghadam, Mina Alimohammadi, Le Liu, Gautam Sethi","doi":"10.1186/s12935-026-04431-y","DOIUrl":"10.1186/s12935-026-04431-y","url":null,"abstract":"<p><p>Solute carrier (SLC) transporters play a central role in tumor metabolism by mediating the uptake of amino acids and sugars required for cancer cell growth and survival. Their proper function is crucial for maintaining cellular homeostasis, and their dysregulation contributes to metabolic reprogramming, tumor progression, and therapy resistance. Recent studies have identified non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, as key regulators of SLC transporter expression and function. This review provides a focused and comprehensive overview of the intricate regulatory networks between ncRNAs and amino acid and sugar transporters within the SLC family, highlighting their implications in cancer. We summarize current evidence on direct and indirect regulatory mechanisms, including transcriptional, post-transcriptional, and epigenetic pathways, and discuss how these interactions reshape cancer metabolism. We highlight existing knowledge gaps, such as context-dependent regulation, indirect regulatory networks, and limited mechanistic validation in vivo. Finally, we discuss the therapeutic potential and challenges of targeting ncRNA-SLC networks. A deeper understanding of these interactions may facilitate the development of novel therapeutic approaches aimed at improving cancer treatment outcomes.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting the Notch signaling pathway in digestive system cancers: from bench to bedside.","authors":"Qingmiao Shi, Shuwen Yang, Siying Li, Chen Xue","doi":"10.1186/s12935-026-04444-7","DOIUrl":"10.1186/s12935-026-04444-7","url":null,"abstract":"<p><p>Digestive system cancers, including malignancies of the oral cavity, esophagus, stomach, liver, pancreas, and colorectum, rank among the most prevalent tumors worldwide, with persistently high incidence and mortality. Notch signaling is a highly conserved pathway that orchestrates essential cellular processes such as differentiation, proliferation, and development; its dysregulation has been increasingly linked to various diseases, particularly digestive system cancers. Accumulating evidence indicates that aberrant Notch signaling is closely associated with the development of these malignancies, where it influences tumor initiation, progression, metastasis, and therapy resistance. Notably, depending on cellular context, Notch signaling may also exhibit tumor-suppressive effects in certain digestive system cancers. Understanding the role of Notch signaling in these tumors is essential for the development of more effective therapeutic strategies. Currently, multiple preclinical studies are investigating agents targeting the Notch pathway. This review summarizes current evidence on Notch signaling in digestive system cancers and points to open questions that warrant further study to inform future therapeutic strategies.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pan-modification proteomics: decoding tumor heterogeneity and guiding the next generation of precision oncology.","authors":"Lulu Wang, Yang Yang, Jing-Hua Yang","doi":"10.1186/s12935-026-04421-0","DOIUrl":"10.1186/s12935-026-04421-0","url":null,"abstract":"<p><p>Tumor heterogeneity is driven by genomic and transcriptomic variation, as well as by extensive protein diversification through post-translational modifications (PTMs), which generate distinct functional proteoforms. These combinatorial modifications reshape signaling, metabolism, and therapeutic response, adding a regulatory layer that conventional proteomics often fails to capture. Recent advances in mass spectrometry and open-modification analysis have enabled systematic profiling of pan-modification proteoforms. This emerging framework provides a deeper mechanistic basis for understanding and resolving tumor heterogeneity. This review explores the integration of multiple PTMs in shaping proteoform identity and the subsequent reprogramming of oncogenic signaling pathways. The impact of advanced analytical frameworks, such as top-down proteomics and spatially resolved mapping, on contemporary tumor biology is assessed. Additionally, we discuss the clinical implications of proteoform-centric biomarkers regarding therapeutic interventions and resistance. By reframing proteomic regulation in terms of pan-modification and proteoform diversity, this review outlines a foundational framework for next-generation precision oncology that interprets proteins not as single entities but as dynamic assemblies of functionally encoded molecular states.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13733074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mykola Lyndin, Michel Janicot, Justus Müller, Peter Schiemann, Gunther Wennemuth
{"title":"NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.","authors":"Mykola Lyndin, Michel Janicot, Justus Müller, Peter Schiemann, Gunther Wennemuth","doi":"10.1186/s12935-026-04438-5","DOIUrl":"10.1186/s12935-026-04438-5","url":null,"abstract":"<p><strong>Background: </strong>The neuronal pentraxin receptor (NPTXR) is mainly expressed in the cytoplasm of a subset of neuronal cells in the cerebral cortex. While NPTXR may be involved in mediating uptake of synaptic material during synapse remodeling or synaptic clustering of AMPA glutamate receptors at a subset of excitatory synapses during embryonic development, NPTXR expression has recently been shown to be elevated in tissues from patients with gastric cancer.</p><p><strong>Methods: </strong>NPTXR protein expression was evaluated in human cancer and healthy tissue samples. We then generated antibody-drug conjugates based on YB-800 (YB-800<sub>ADCs</sub>), a fully humanized monoclonal antibody selectively targeting NPTXR. The cross-reactivity of YB-800 and YB-800<sub>ADCs</sub> were assessed, as well as their tumor inhibitory effects in experimental tumor models.</p><p><strong>Results: </strong>NPTXR protein was highly and consistently expressed in human tissue samples from multiple cancer types but only minimally expressed, if at all, in healthy tissues. Treatment with YB-800<sub>ADCs</sub> inhibited tumor cell proliferation/survival in engineered HEK293 cells overexpressing the human NPTXR. YB-800<sub>ADCs</sub> were also found to have pronounced anti-tumor effects in mice bearing NPTXR-expressing HEK293 tumors at well-tolerated doses. Initial anti-tumor findings were further confirmed using a naturally occurring NPTXR-expressing human bladder PDX model.</p><p><strong>Conclusions: </strong>NPTXR is an oncofetal protein that is highly expressed in multiple human cancers but minimally expressed in healthy tissues. We have established NPTXR as a new tumor marker and have developed antibody-drug conjugates using YB-800, a novel, first-in-class, humanized monoclonal antibody targeting the human NPTXR. Initial results demonstrate that YB-800<sub>ADCs</sub> have pronounced anti-tumor effects in vivo in NPTXR-expressing cancer cells. Continued evaluation of YB-800<sub>ADCs</sub> is warranted.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Repurposing thioridazine as a novel treatment for melanoma brain metastasis.","authors":"Tobias Wikerholmen, Erlend Moen Taule, Katharina Sarnow, Emma Rigg, Hege Avsnes Dale, Terje Sundstrøm, Jian Wang, Frits Thorsen","doi":"10.1186/s12935-026-04440-x","DOIUrl":"10.1186/s12935-026-04440-x","url":null,"abstract":"<p><strong>Background: </strong>A substantial proportion of patients with melanoma brain metastases (MBM), especially those symptomatic at therapy start, continue to respond poorly to currently available systemic therapies, including immune checkpoint inhibitors. Durable systemic treatment options beyond established regimens remain limited for this patient population. Drug repurposing offers a rapid translational path for identifying novel therapeutic strategies. Thioridazine, a phenothiazine antipsychotic with known blood-brain barrier permeability, has shown anticancer effects in several malignancies but has not previously been evaluated in MBM. This study investigates the anti-tumoral potential and underlying mechanisms of thioridazine in patient-derived MBM cell lines.</p><p><strong>Methods: </strong>Cytotoxic, anti-proliferative, and anti-migratory effects of thioridazine were assessed in four MBM cell lines (H1, H2, H3, H10) using monolayer and soft agar viability assays, live-cell imaging, and clonogenic assays. Potential off-target toxicity was evaluated using fetal rat brain organoids (FRBOs). Mechanistic effects were examined using Annexin V/PI flow cytometry, Western blotting of apoptosis- and autophagy-related proteins (cleaved PARP1, cleaved caspase-3, Bcl-2, p62, LC3A/B), and confocal microscopy to assess autophagosome formation and lysosomal dynamics.</p><p><strong>Results: </strong>Thioridazine reduced viability of MBM cells in a dose-dependent manner, with IC<sub>50</sub> values ranging from 8.7 to 12.0 µM. Anchorage-independent growth was similarly inhibited. FRBOs displayed no treatment-associated cytotoxicity at MBM-relevant doses in vitro. Thioridazine markedly suppressed MBM cell proliferation, migration, and clonogenic growth in a dose-dependent manner. Apoptosis induction was inconsistent across cell lines, with variable activation of cleaved PARP1, cleaved caspase-3, and Bcl-2. In contrast, autophagy-associated markers p62 and LC3A/B were consistently upregulated, accompanied by intracellular accumulation of punctate autophagosomes and altered lysosomal morphology, indicating impaired autophagic flux.</p><p><strong>Conclusions: </strong>Thioridazine demonstrates robust anti-tumoral activity in MBM cells in vitro while sparing healthy brain organoid tissue. Its cytotoxic effects appear independent of classical apoptosis and instead correlate with disrupted autophagic flux and altered lysosomal dynamics. These findings highlight thioridazine as a promising candidate for therapeutic repurposing in MBM and support further investigation into its autophagy-modulating mechanisms.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sina Taghvimi, Zoleikha Asadi, Sajad Ehtiati, Mahzad Nikbakhtrad, Zeinab Chaharlashkar, Fereshteh Rahdan, Seyyed Hossein Khatami, Seyed Mohammad Salehi Behbahani, Hamidreza Zaheri, Ahmad Movahedpour, Hassan Ghasemi, Elahe Soltani Fard
{"title":"Biosensors as transformative tools for detection of lung cancer based on non-coding RNA.","authors":"Sina Taghvimi, Zoleikha Asadi, Sajad Ehtiati, Mahzad Nikbakhtrad, Zeinab Chaharlashkar, Fereshteh Rahdan, Seyyed Hossein Khatami, Seyed Mohammad Salehi Behbahani, Hamidreza Zaheri, Ahmad Movahedpour, Hassan Ghasemi, Elahe Soltani Fard","doi":"10.1186/s12935-026-04435-8","DOIUrl":"10.1186/s12935-026-04435-8","url":null,"abstract":"<p><p>Lung cancer remains one of the most prevalent and lethal malignancies worldwide, resulting in approximately 1.5 million deaths annually. Currently, more than 75% of cases are diagnosed at an advanced stage due to the lack of effective early detection methods. Although several conventional diagnostic techniques are available, many exhibits limited sensitivity for early-stage detection and are often associated with high costs and invasiveness. Therefore, there is an urgent need for more accurate, cost-effective, and rapid approaches for early screening. Numerous lung cancer-associated non-coding RNAs (ncRNAs) have been extensively investigated as promising biomarkers for diagnosis, prognosis, and therapeutic monitoring. To leverage these biomarkers, various nanomaterial-enhanced biosensors-utilizing electrochemical, optical, and electromechanical platforms-have been developed for the rapid and selective detection of ncRNAs. This review provides a comprehensive overview of recent advances in nanobiosensor technologies for detecting lung cancer-associated ncRNAs, highlighting their substantial diagnostic potential while critically addressing the technical bottlenecks, reproducibility challenges, and regulatory hurdles that must be overcome for their successful clinical translation.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Characteristics of fusion genes in breast cancer.","authors":"Zhuo Gu, Xiang Zhong, Hanyue Ma, Mengxue Song, Qiyan Feng, Yuhui Huang, Guo-Qin Jiang, Jinrong Wei","doi":"10.1186/s12935-026-04434-9","DOIUrl":"10.1186/s12935-026-04434-9","url":null,"abstract":"<p><p>Fusion genes, arising from aberrant genomic rearrangements, represent critical oncogenic drivers with distinct oncogenic functions. Although relatively uncommon in breast cancer, accumulating evidence suggests that fusion genes contribute to tumor initiation, progression, and therapeutic resistance. This review first summarizes the molecular mechanisms underlying fusion gene formation, their frequency and subtype distribution, and advances in detection technologies in breast cancer. We then discuss how fusion genes reprogram oncogenic signaling pathways and mediate resistance to conventional and targeted therapies. Finally, we evaluate their translational potential as diagnostic biomarkers and therapeutic targets, emphasizing opportunities for precision oncology. By integrating current insights, this review underscores the multifaceted roles of fusion genes in breast cancer biology and highlights their promise for guiding the development of more effective, personalized treatment strategies.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}